Connect with us

Cannabis News

GOP Senator Says Congress Must ‘Step Up’ And Regulate Marijuana, While Exploring Its ‘Efficacy’ For PTSD And Pain

Published

5 months ago

on

A Senator GOP says that the federal government needs “step” and must explore the regulatory framework of Marijuana and, that it should be a way to study the “efficiency of” efficiency “for health conditions.

Thom Tillis (R-NC) made comments made by the Senate Judiciary Commission on Wednesday, where President Donald Trump and the judicial denominator Candidate drugs testified for the Director of Office of National Control Policy (Ondcp) Before possible votes of assertion.

Tillis said that the Cory Booker (D-NJ) had made points about Cannabis policy “when they are very well taken”, “Congress is not playing his work.”

As more states are legalized, public support will be worried about public support “if not serious about regulatory regulations,” argued the Republican Senator.

Listen to the senator’s remarks about marijuana regulation 2:44:10:

“Congress must take step and try to manage (and) in the areas that exploit its effectiveness, the treatment and pain of people with PTSD, Tillis said.” But we have to step. “

“In the time left here, we hope we can get something,” he said he did not reset again.

The earlier hearing, Sara Carter, Sara Carter (name Sara Bailey). It is what he has been addressed to the questions, and the administration kept holding “all options” on the table. While describing the reform of cannabis as “bipartisan”.

The book indicated that Carter had support about access to Marijuana Marijuana in 2023Congress has had “Bipartisan’s auditions here about military workers talking about the transformative impact of post-traumatic stress disorder (PTSD)”.

As the senator agrees to end the banned banabis ban, Joe Biden began under the former president of Joe Biden and Trump said that he would definitely take the decision in the last month “would be a step in the right direction.”

The Tillis did not specifically weighed in the proposal to move cannabis to program II (CSA) of Substance Act III (CSA). But the echo had the need to evaluate the regular marijuana framework of Marijuana in the federal level of Marijuana.

–
Marijuana is a moment Monitoring of hundreds of cannabis, psychedelic and drug policy invoices This year’s state legislatures and congresses. Patreon supporters At least $ 25 / monthly enter our interactive maps, graphs and listening to the listening calendar, so they do not lose development.

Learn more about us Marihuana Bill Tracker and become Assistant Patreon to get access.
–

In the Judiciary Committee on June, Tillis said Marijuana legalization opponents “They lost” the struggle to keep ban And the “time” is to cope with this reality, creating a regulatory framework for treatment of cannabis “in the same way we do alcohol and tobacco, to establish policies without federal intervention.

In February, the senator also raised the subject during the Senate Bank Committee, Saying “Rexamine (Marijuana Federal Laws) saying”. “ At the same time, “We are sure it shouldn’t be done” legislation that would accept legislation to prevent penalizing the banks working with the State Canavy business.

“If someone wants to practice the rules of the road and want to make the industry, in a cohesive and sustainable way, the skirt is not permanently, it is still illegal at the federal level.

Tillis said that last December, hopeful conference will be “discussion” Marijuana may create a federal regulatory framework In 2025, he added that he would personally vote to legalize cannabis federally.

Last year, Senator also said “Supports the creation of a comprehensive regulations Marijuana treats like tobacco, “argued” The federal government must represent a safe way to allow this market to happen. “

Tillis in April Sen. TED Budd (R-NC) entered Federal, State and Local Officials What to Ask The steps were enforcing the marijuana ban As Indian tribes was prepared for recreational cannabis sales within its land within North Carolina.

Meanwhile, in 2017, Tillis also collaborated with bandides in a bill Pay attention to researchers to marijuana access for its medical benefits And the National Institute of Abuse Drugs (NIDA) requires the development of good manufacturing practices for growing and producing research canvas.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

Become patreon guard!

(Tagstotranslate) highlighted

Related Topics:
Continue Reading

Cannabis News

Greenhouses and more at Fruit Logistica Berlin

Published

12 hours ago

on

February 9, 2026

By











New varieties, new concepts, new packaging, new products, new faces – there was a lot to do in Berlin last week. And, new travel schedules too: due to the black ice, many visitors traveling by plane had to extend their stay or find an alternative mode of transport – or both.

Click here for the photo report.

© Arlette Sijmonsma | MMJDaily.com

Fortunately, our bus drivers got us home safely to the Netherlands, and we were able to take all the photos of the greenhouse suppliers, growers and other related parties, so take a seat and enjoy our Fruit Logistica photo report!

There will be more updates this week, as well as extensive reports from our international Freshplaza colleagues, focused on the fresh produce industry.

Click here for the photo report.










Continue Reading

Cannabis News

Alaska Government Task Force Recommends Legalizing Psychedelic Therapy Upon FDA Approval

Published

13 hours ago

on

February 9, 2026

By

An Alaska psychedelic task force is recommending that the state move forward with plans to provide regulated access to psychedelics if the federal Food and Drug Administration (FDA) allows medical use of substances such as psilocybin and MDMA.

According to a law approved in 2024, after working for about a year studying the issue, Alaska Legislative Task Force on Psychedelic Drug Regulation released its findings and recommendations on Thursday.

“Alaska has one of the nation’s highest rates of domestic violence survivors and combat veterans suffering from PTSD, and many Alaskans continue to struggle with traditional treatments,” Sen. Forrest Dunbar (D), the task force’s leader, said in a press release.

“Our approach to these new medical therapies must be properly and independently evaluated so that if the legislature were to make policy changes, we will do so with empirical data in a properly controlled environment,” the senator said.

The panel’s report lists a number of findings based on a review of the scientific literature and expert testimony. This includes findings that some psychedelics do indeed have “potential therapeutic uses” and that “there is a particular focus on the use of these therapies for veterans, survivors of assault and interpersonal violence, and others with post-traumatic stress disorder (PTSD).

Members emphasized the importance of delivering psychedelic therapies in partnership with “multiple types of providers” to provide comprehensive treatment, rather than leaving it up to the patient.

Among its recommendations, the task force said, “If psychedelic medical therapies are approved by the FDA, the state should take steps to allow them to be used in Alaska, rather than ban their use.”

Alaska regulators should also identify clinical task forces, “whose role is to regularly review up-to-date studies and the evidence base to make recommendations, and rely on those entities to provide ongoing guidance on the use of these therapies,” he said.

“As much as possible, reserve the use of state statute for broad enabling language and essential components of a regulatory structure, and leave most regulatory decisions to the appropriate boards and agencies,” another recommendation reads. “Regulations still require a robust public process to be approved, but they are more predictable and can be updated or changed more easily than statutory amendments that require legislative action.”

“The appropriate parameters for the use of these therapies are likely to change over time as the evidence base matures and FDA approval may be granted for multiple therapies,” he said.

If the FDA continues to approve any psychedelics for medical use, the panel said the Alaska State Board of Medicine should update its guidelines for prescribing controlled substances to include new therapies.

Additionally, if the FDA approves psychedelic drugs and the Drug Enforcement Administration (DEA) federally reschedules substances such as psilocybin, Alaska “should fully reflect federal programming and Risk Evaluation and Mitigation Strategies (REMS), without adding duplicative or conflicting state regulations, and follow the rules for determining whether a DEA license is required.” the report he says

“This approach respects federal science and facilitates access for patients and providers,” he continues.

Additionally, as lawmakers and regulators await a federal decision to advance psychedelic therapies, states should consider legislation to “incorporate the recommendations made in this report to encourage statewide implementation action.”

“Legislation on triggers would require addressing various process and regulatory issues, such as the role and involvement of professional licensing boards, state agencies, and the Controlled Substances Advisory Committee,” the task force said.

The report also says that psychedelic reform should include military veterans’ access to FDA-approved therapies, which could involve working with the US Department of Veterans Affairs (VA) to identify opportunities to participate in clinical trials and pilot programs using new drugs.

“The grant should be considered to ensure active efforts by the American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) to develop billing codes that will promote sufficient reimbursement for the provision of psychedelic therapy, which are essential to ensure patient access post-FDA approval,” the panel said.

Rep. Justin Ruffridge (R), who also serves as co-chair of the psychedelic panel, said the task force “focused on preparing Alaska for potential federal approval of psychedelic therapies.”

“These recommendations came from months of collaboration and work by medical professionals, advocates and legislators who focused on patient safety, evidence-based care and access, especially for those who have not seen progress through traditional treatments,” he said.

So far two other states have facilitated fully functioning psychedelic programs. Oregon voters legalized the therapeutic psilocybin in 2020and Colorado’s program was approved at the ballot box in 2022, with the state’s governor signing the legislation a year later to create the regulatory framework for the program

Meanwhile, a campaign in Alaska announced in December that it did not get enough signaturesAn initiative to legalize some psychedelics like psilocybin and DMT on the 2026 state ballot.– but the activists have emphasized that “the work is far from over” as they focus on putting the reform measure before the voters in 2028.

“While we won’t be on the ballot in 2026, we’re still on track for 2028, and with the determination, focus and support of our community, we’ll continue to move forward,” Natural Medicine Alaska said in December. “This movement is gaining momentum every day. In fact, 65 percent of Alaskans support this initiative, and that number continues to grow.”

A pre-campaign policy outline explained that the proposal is “under construction”. The Natural Medicine Health Act of 2022 passed by Colorado votersunder last year facilitators administered the state’s first legal dose of psilocybin.

A 2024 poll found that nearly half (49.4 percent) of Alaskan adults would support a ballot measure more broadly. remove criminal penalties for the use of substances such as psilocybin mushrooms.

That support rose significantly—to nearly two-thirds (65 percent)—when participants were told that Alaska has high rates of mental illness that could be treated with psychedelics.

Photo elements courtesy of the user carlosemmaskype and Apollo.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Anti legalization group fails to collect signatures to roll back laws

Published

2 days ago

on

February 8, 2026

By











A Maine campaign seeking to significantly roll back the state’s marijuana law failed to submit signatures this week for the November 2026 ballot, meaning anti-cannabis activists will have to move to 2027 if they hope to get the issue before voters.

Amid criticism from reform advocates, industry players and some lawmakers for allegedly deceptive signature-gathering tactics, Mainers for a Safe and Healthy Future apparently couldn’t make the cut by the Feb. 2 deadline.

“Cannabis orders were not returned yesterday,” Assistant Secretary of State for Communications Jana Spaulding told Cannabis Business Times on Tuesday. In Maine, that doesn’t mean the campaign has to start from scratch, though, because they can still put the proposition on next year’s ballot. A Republican Maine lawmaker and marijuana industry advocates raised the alarm last month that prohibitionist campaigners were using deceptive petitions to get voters to sign the petition.

A video shared by Rep. David Boyer (R) appeared to feature an image and audio recording of a person gathering signatures for the ballot measure, in which he grossly misrepresented what the cannabis proposal would accomplish, saying its main goal was to ensure the product’s safety through improved testing.

Read more at Marijuana Moment










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media